{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:54:51Z","timestamp":1789584891140,"version":"build-2803163510"},"reference-count":41,"publisher":"Bioscientifica","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":424,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Somatostatin receptor analogues are well-established in the treatment of metastatic gastro-enteropancreatic neuroendocrine tumours (GEP-NETs), especially for symptom control in patients with the carcinoid syndrome, and to control tumour growth. However, they need to be discontinued before peptide receptor radionuclide therapy (PRRT) as they may saturate the somatostatin receptor 2 (SSTR2) and prevent binding of the radioactive ligand.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>We evaluated the effects of the novel somatostatin analogue paltusotine on 18F-SiTATE radioligand uptake and on GEP-NET cell viability in comparison to octreotide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Paltusotine and octreotide were evaluated in varying concentrations in an 18F-SiTATE uptake assay using stable hSSTR2 over-expressing BON-1 cells, and in a cell viability assay utilising different NET cell lines and human patient-derived GEP-NET primary cultures (n = 13).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Low, clinically-relevant concentrations of paltusotine (7.3\u201325.4 nM) demonstrated no influence on cellular radioligand uptake compared to the control. In contrast, octreotide reduced radioligand uptake at low, clinically-relevant concentrations (7.3\u201325.4 nM) and led to a further significant reduction of radioligand uptake at higher concentrations (73\u2013508 nM). Both paltusotine and octreotide showed overall little or no significant anti-tumour effects in vitro in NET cell lines. However, in contrast to octreotide, paltusotine led to a slight decrease in cell viability of patient-derived GEP-NET primary cultures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Treatment with paltusotine did not significantly reduce radioligand binding of 18F-SiTATE in vitro, indicating no influence on SSTR2 targeting. This might enable a continuation of somatostatin receptor analogue therapy with paltusotine during PRRT, potentially improving symptom control in GEP-NET patients with the carcinoid syndrome.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/eo-25-0041","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T15:36:21Z","timestamp":1759505781000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-15","source":"Crossref","is-referenced-by-count":2,"title":["Paltusotine versus octreotide: different effects on radioligand uptake in neuroendocrine tumours"],"prefix":"10.1530","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7795-1395","authenticated-orcid":true,"given":"Katharina","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Internal Medicine IV, LMU University Hospital, LMU Munich 1 , ,","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph J","family":"Auernhammer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV, LMU University Hospital, LMU Munich 1 , ,","place":["Munich, Germany"]},{"name":"Interdisciplinary Center of Neuroendocrine Tumors of The GastroEnteroPancreatic System (GEPNET-KUM, ENETS Centre of Excellence), LMU University Hospital 2 , ,","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Lindner","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, LMU University Hospital, LMU Munich 3 , ,","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Zacherl","sequence":"additional","affiliation":[{"name":"Interdisciplinary Center of Neuroendocrine Tumors of The GastroEnteroPancreatic System (GEPNET-KUM, ENETS Centre of Excellence), LMU University Hospital 2 , ,","place":["Munich, Germany"]},{"name":"Department of Nuclear Medicine, LMU University Hospital, LMU Munich 3 , ,","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A","family":"Werner","sequence":"additional","affiliation":[{"name":"Interdisciplinary Center of Neuroendocrine Tumors of The GastroEnteroPancreatic System (GEPNET-KUM, ENETS Centre of Excellence), LMU University Hospital 2 , ,","place":["Munich, Germany"]},{"name":"Department of Nuclear Medicine, LMU University Hospital, LMU Munich 3 , ,","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Maurer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV, LMU University Hospital, LMU Munich 1 , ,","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Peischer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV, LMU University Hospital, LMU Munich 1 , ,","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Hamati","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV, LMU University Hospital, LMU Munich 1 , ,","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian P","family":"Hungbauer","sequence":"additional","affiliation":[{"name":"Interdisciplinary Center of Neuroendocrine Tumors of The GastroEnteroPancreatic System (GEPNET-KUM, ENETS Centre of Excellence), LMU University Hospital 2 , ,","place":["Munich, Germany"]},{"name":"Department of General, Visceral and Transplantation Surgery, LMU University Hospital, LMU Munich 4 , ,","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kn\u00f6sel","sequence":"additional","affiliation":[{"name":"Interdisciplinary Center of Neuroendocrine Tumors of The GastroEnteroPancreatic System (GEPNET-KUM, ENETS Centre of Excellence), LMU University Hospital 2 , ,","place":["Munich, Germany"]},{"name":"Institute of Pathology, Faculty of Medicine, LMU Munich 5 , ,","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Reul","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich 6 , ,","place":["Zurich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Kuzmenko","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich 6 , ,","place":["Zurich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Vetter","sequence":"additional","affiliation":[{"name":"Department of Visceral and Transplantation Surgery, University Hospital Zurich 7 , ,","place":["Zurich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Oberholzer","sequence":"additional","affiliation":[{"name":"Department of Visceral and Transplantation Surgery, University Hospital Zurich 7 , ,","place":["Zurich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Maccio","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Pathology, University Hospital Zurich 8 , ,","place":["Zurich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Beuschlein","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV, LMU University Hospital, LMU Munich 1 , ,","place":["Munich, Germany"]},{"name":"Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich 6 , ,","place":["Zurich, Switzerland"]},{"name":"The LOOP Zurich \u2013 Medical Research Center 9 , ,","place":["Zurich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Reincke","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV, LMU University Hospital, LMU Munich 1 , ,","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8906-2563","authenticated-orcid":true,"given":"Constanze","family":"Hantel","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich 6 , ,","place":["Zurich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3541-3767","authenticated-orcid":true,"given":"Karel","family":"Pacak","sequence":"additional","affiliation":[{"name":"AKESO 10 , ,","place":["Prague, Czech Republic"]},{"name":"11Palacky University, Olomouc, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1176-6186","authenticated-orcid":true,"given":"Ashley B","family":"Grossman","sequence":"additional","affiliation":[{"name":"Green Templeton College, University of Oxford 12 , ,","place":["Oxford, UK"]},{"name":"NET Unit, ENETS Centre of Excellence, Royal Free Hospital 13 , ,","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Zitzmann","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV, LMU University Hospital, LMU Munich 1 , ,","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7064-590X","authenticated-orcid":true,"given":"Svenja","family":"N\u00f6lting","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV, LMU University Hospital, LMU Munich 1 , ,","place":["Munich, Germany"]},{"name":"Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich 6 , ,","place":["Zurich, Switzerland"]},{"name":"ENETS Centre of Excellence Zurich, University Hospital Zurich 14 , ,","place":["Zurich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"key":"2026070713295932700_bib1","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13146","article-title":"European neuroendocrine tumor society (ENETS) 2022 guidance paper for carcinoid syndrome and carcinoid heart disease","volume":"34","author":"Grozinsky-Glasberg","year":"2022","journal-title":"J Neuroendocrinol"},{"key":"2026070713295932700_bib2","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"key":"2026070713295932700_bib3","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"2026070713295932700_bib4","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann Oncol"},{"key":"2026070713295932700_bib5","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13318","article-title":"European neuroendocrine tumor society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes","volume":"35","author":"Hofland","year":"2023","journal-title":"J Neuroendocrinol"},{"key":"2026070713295932700_bib6","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13423","article-title":"European neuroendocrine tumor society (ENETS) 2024 guidance paper for the management of well-differentiated small intestine neuroendocrine tumours","volume":"36","author":"Lamarca","year":"2024","journal-title":"J Neuroendocrinol"},{"key":"2026070713295932700_bib7","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","article-title":"The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours","volume":"40","author":"Bodei","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026070713295932700_bib8","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000475526","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine neoplasia: peptide receptor radionuclide therapy with radiolabeled somatostatin analogues","volume":"105","author":"Hicks","year":"2017","journal-title":"Neuroendocrinology"},{"key":"2026070713295932700_bib9","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/COC.0000000000000903","article-title":"ACR-ACNM-ASTRO-SNMMI practice parameter for Lutetium-177 (Lu-177) DOTATATE therapy","volume":"45","author":"Love","year":"2022","journal-title":"Am J Clin Oncol"},{"key":"2026070713295932700_bib10","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1021\/acsmedchemlett.2c00431","article-title":"Discovery of paltusotine (CRN00808), a potent, selective, and orally bioavailable non-peptide SST2 agonist","volume":"14","author":"Zhao","year":"2023","journal-title":"ACS Med Chem Lett"},{"key":"2026070713295932700_bib11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1210\/clinem\/dgae385","article-title":"Acromegaly disease control maintained after switching from injected somatostatin receptor ligands to oral paltusotine","volume":"110","author":"Gadelha","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713295932700_bib12","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvae163.1201","article-title":"12535 Efficacy and safety of once-daily oral paltusotine in medically untreated patients with acromegaly: results from the phase 3, randomized, placebo-controlled Pathfndr-2 study","volume":"8","author":"Biller","year":"2024","journal-title":"J Endocr Soc"},{"key":"2026070713295932700_bib13","article-title":"Once-daily oral paltusotine in the treatment of patients with carcinoid syndrome: results from a phase 2, randomized, parallel-group study","volume":"108","author":"Chauhan","year":"2024","journal-title":"Endocr Abstr"},{"key":"2026070713295932700_bib14","volume-title":"22nd Annual ENETS Conference 2025","author":"Kim","year":"2025"},{"key":"2026070713295932700_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178375","article-title":"The MTH1 inhibitor TH588 demonstrates anti-tumoral effects alone and in combination with everolimus, 5-FU and gamma-irradiation in neuroendocrine tumor cells","volume":"12","author":"Aristizabal Prada","year":"2017","journal-title":"PLoS One"},{"key":"2026070713295932700_bib16","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2024.2412371","article-title":"Peptide-guided adaptor-CAR T-Cell therapy for the treatment of SSTR2-expressing neuroendocrine tumors","volume":"13","author":"Pellegrino","year":"2024","journal-title":"OncoImmunology"},{"key":"2026070713295932700_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000545073","article-title":"Upregulation of SSTR2 expression and radioligand binding of [18F]SiTATE in neuroendocrine tumour cells with combined inhibition of class I HDACs and LSD1","volume":"115","author":"Auernhammer","year":"2025","journal-title":"Neuroendocrinology"},{"key":"2026070713295932700_bib18","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/clinem\/dgae241","article-title":"Opposing effects of cannabidiol in patient-derived neuroendocrine tumor, pheochromocytoma\/paraganglioma primary cultures","volume":"109","author":"Wang","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713295932700_bib19","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s11102-021-01201-z","article-title":"Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers","volume":"25","author":"Madan","year":"2022","journal-title":"Pituitary"},{"key":"2026070713295932700_bib20","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1210\/jc.2012-1179","article-title":"Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression","volume":"97","author":"Tuvia","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713295932700_bib21","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1210\/en.2019-00410","article-title":"Synergistic highly potent targeted drug combinations in different pheochromocytoma models including human tumor cultures","volume":"160","author":"Fankhauser","year":"2019","journal-title":"Endocrinology"},{"key":"2026070713295932700_bib22","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1530\/eje.0.1460707","article-title":"SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile","volume":"146","author":"Bruns","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"2026070713295932700_bib23","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1177\/0091270005277936","article-title":"Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles","volume":"45","author":"Astruc","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"2026070713295932700_bib24","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1007\/s00259-022-06094-z","article-title":"The effect of long-acting somatostatin analogues on the uptake of [(177)Lu]Lu-HA-DOTATATE","volume":"50","author":"Veerman","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026070713295932700_bib25","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s00259-023-06375-1","article-title":"Letter to the editor regarding \u201cthe effect of long-acting somatostatin analogs on the uptake of [(177)Lu]Lu-HA-DOTATATE\u201d","volume":"51","author":"Wang","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026070713295932700_bib26","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1158\/1078-0432.CCR-18-0947","article-title":"The role of adding somatostatin analogues to peptide receptor radionuclide therapy as a combination and maintenance therapy","volume":"24","author":"Yordanova","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2026070713295932700_bib27","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1007\/s00259-020-04712-2","article-title":"Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice","volume":"47","author":"Prasad","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026070713295932700_bib28","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"(177)Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026070713295932700_bib29","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"2026070713295932700_bib30","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1007\/s11307-021-01600-5","article-title":"Prospective within-patient assessment of the impact of an unlabeled octreotide pre-dose on the biodistribution and tumor uptake of (68)Ga DOTATOC as assessed by dynamic whole-body PET in patients with neuroendocrine tumors: implications for diagnosis and therapy","volume":"23","author":"Lodge","year":"2021","journal-title":"Mol Imaging Biol"},{"key":"2026070713295932700_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.992316","article-title":"Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [(18)F]SiTATE","volume":"13","author":"Eschbach","year":"2023","journal-title":"Front Oncol"},{"key":"2026070713295932700_bib32","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.2967\/jnumed.111.089276","article-title":"Treatment with octreotide does not reduce tumor uptake of (68)Ga-DOTATATE as measured by PET\/CT in patients with neuroendocrine tumors","volume":"52","author":"Haug","year":"2011","journal-title":"J Nucl Med"},{"key":"2026070713295932700_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2024.101906","article-title":"Treatment of acromegaly with the nonpeptide, highly selective somatostatin receptor type 2 agonist paltusotine","volume":"38","author":"Wildemberg","year":"2024","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2026070713295932700_bib34","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/s41467-023-36673-z","article-title":"Prospect of acromegaly therapy: molecular mechanism of clinical drugs octreotide and paltusotine","volume":"14","author":"Zhao","year":"2023","journal-title":"Nat Commun"},{"key":"2026070713295932700_bib35","doi-asserted-by":"crossref","DOI":"10.1530\/JOE-23-0298","article-title":"Somatostatin receptors and the associated intracellular machinery: the two sides of the coin","volume":"260","author":"Campana","year":"2024","journal-title":"J Endocrinol"},{"key":"2026070713295932700_bib36","doi-asserted-by":"crossref","first-page":"37","DOI":"10.17925\/EE.2024.20.1.9","article-title":"Clinical pharmacology of oral octreotide capsules for the treatment of acromegaly","volume":"20","author":"Uygur","year":"2024","journal-title":"Touchrev Endocrinol"},{"key":"2026070713295932700_bib37","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1530\/EJE-15-1042","article-title":"Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly","volume":"174","author":"Strasburger","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"2026070713295932700_bib38","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3389\/fendo.2018.00146","article-title":"Octreotide does not inhibit proliferation in five neuroendocrine tumor cell lines","volume":"9","author":"Exner","year":"2018","journal-title":"Front Endocrinol"},{"key":"2026070713295932700_bib39","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1530\/ERC-19-0086","article-title":"Effects of novel somatostatin-dopamine chimeric drugs in 2D and 3D cell culture models of neuroendocrine tumors","volume":"26","author":"Herrera-Martinez","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"2026070713295932700_bib40","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1530\/ERC-21-0355","article-title":"Personalized drug testing in human pheochromocytoma\/paraganglioma primary cultures","volume":"29","author":"Wang","year":"2022","journal-title":"Endocr Relat Cancer"},{"key":"2026070713295932700_bib41","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/ejendo\/lvae163","article-title":"Impact of sex hormones on pheochromocytomas, paragangliomas, and gastroenteropancreatic neuroendocrine tumors","volume":"192","author":"Wang","year":"2025","journal-title":"Eur J Endocrinol"}],"container-title":["Endocrine Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eo.bioscientifica.com\/view\/journals\/eo\/5\/1\/EO-25-0041.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eo.bioscientifica.com\/downloadpdf\/journals\/eo\/5\/1\/EO-25-0041.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/eo\/article-pdf\/doi\/10.1530\/EO-25-0041\/193971\/eo-25-0041.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/eo\/article-pdf\/doi\/10.1530\/EO-25-0041\/193971\/eo-25-0041.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:51:32Z","timestamp":1783446692000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/eo\/article\/5\/1\/e250041\/34755\/Paltusotine-versus-octreotide-different-effects-on"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.1530\/eo-25-0041","relation":{},"ISSN":["2634-4793"],"issn-type":[{"value":"2634-4793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,1]]},"article-number":"e250041"}}